1. Choi H, Kang SH, Jeong SW, et al. Lipid-lowering efficacy of combination therapy with moderate-intensity statin and ezetimibe versus high-intensity statin monotherapy: a randomized, open-label, non-inferiority trial from Korea. J Lipid Atheroscler 2023;12:277–289.

2. Kang Y, Park JM, Lee SH. Moderate-intensity rosuvastatin/ezetimibe combination versus quadruple-dose rosuvastatin monotherapy: a meta-analysis and systemic review. Yonsei Med J 2024;65:19–26.

3. Park KY, Hong S, Kim KS, Han K, Park CY. Trends in prevalence of hypertriglyceridemia and related factors in Korean adults: a serial cross-sectional study. J Lipid Atheroscler 2023;12:201–212.

4. Tarim BA, Fici F, Tengiz I, et al. Do statins counteract the effect of antidiabetic drugs? Results of the SCEAD study. Yonsei Med J 2023;64:175–180.

5. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111–188.

6. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019;73:3168–3209.

7. Jin ES, Shim JS, Kim SE, et al. Dyslipidemia fact sheet in South Korea, 2022. J Lipid Atheroscler 2023;12:237–251.

8. Hong S, Han K, Park JH, Yu SH, Lee CB, Kim DS. Higher non-high-density lipoprotein cholesterol was higher associated with cardiovascular disease comparing higher LDL-C in nine years follow up: cohort study. J Lipid Atheroscler 2023;12:164–174.

9. Simha V. Management of hypertriglyceridemia. BMJ 2020;371:m3109.

10. Chen HJ, Chuang SY, Chang HY, Pan WH. Energy intake at different times of the day: Its association with elevated total and LDL cholesterol levels. Nutr Metab Cardiovasc Dis 2019;29:390–397.

11. Magriplis E, Marakis G, Kotopoulou S, et al. Trans fatty acid intake increases likelihood of dyslipidemia especially among individuals with higher saturated fat consumption. Rev Cardiovasc Med 2022;23:130.

12. Hu FB, Manson JE, Willett WC. Types of dietary fat and risk of coronary heart disease: a critical review. J Am Coll Nutr 2001;20:5–19.

13. Sun Y, Neelakantan N, Wu Y, Lote-Oke R, Pan A, van Dam RM. Palm oil consumption increases LDL cholesterol compared with vegetable oils low in saturated fat in a meta-analysis of clinical trials. J Nutr 2015;145:1549–58.

14. Fernandez ML, West KL. Mechanisms by which dietary fatty acids modulate plasma lipids. J Nutr 2005;135:2075–2078.

15. Hannon BA, Khan NA, Teran-Garcia M. Nutrigenetic contributions to dyslipidemia: a focus on physiologically relevant pathways of lipid and lipoprotein metabolism. Nutrients 2018;10:1404.

16. Mozaffarian D, Katan MB, Ascherio A, Stampfer MJ, Willett WC. Trans fatty acids and cardiovascular disease. N Engl J Med 2006;354:1601–1613.

17. Oteng AB, Kersten S. Mechanisms of action of trans fatty acids. Adv Nutr 2020;11:697–708.

18. Jung CH, Choi KM. Impact of high-carbohydrate diet on metabolic parameters in patients with type 2 diabetes. Nutrients 2017;9:322.

19. Chawla S, Tessarolo Silva F, Amaral Medeiros S, Mekary RA, Radenkovic D. The effect of low-fat and low-carbohydrate diets on weight loss and lipid levels: a systematic review and meta-analysis. Nutrients 2020;12:3774.

20. Dong T, Guo M, Zhang P, Sun G, Chen B. The effects of low-carbohydrate diets on cardiovascular risk factors: a meta-analysis. PLoS One 2020;15:e0225348.

21. Fechner E, Smeets ETHC, Schrauwen P, Mensink RP. The effects of different degrees of carbohydrate restriction and carbohydrate replacement on cardiometabolic risk markers in humans-a systematic review and meta-analysis. Nutrients 2020;12:991.

22. David Wang D, Sievenpiper JL, de Souza RJ, et al. Effect of fructose on postprandial triglycerides: a systematic review and meta-analysis of controlled feeding trials. Atherosclerosis 2014;232:125–133.

23. Kim SA, Shin S. Red meat and processed meat consumption and the risk of dyslipidemia in Korean adults: a prospective cohort study based on the Health Examinees (HEXA) study. Nutr Metab Cardiovasc Dis 2021;31:1714–1727.

24. Welsh JA, Sharma A, Abramson JL, Vaccarino V, Gillespie C, Vos MB. Caloric sweetener consumption and dyslipidemia among US adults. JAMA 2010;303:1490–1497.

25. Haslam DE, Peloso GM, Herman MA, et al. Beverage consumption and longitudinal changes in lipoprotein concentrations and incident dyslipidemia in US adults: the Framingham Heart study. J Am Heart Assoc 2020;9:e014083.

26. Stanhope KL. Sugar consumption, metabolic disease and obesity: the state of the controversy. Crit Rev Clin Lab Sci 2016;53:52–67.

28. Donat-Vargas C, Sandoval-Insausti H, Rey-García J, et al. High consumption of ultra-processed food is associated with incident dyslipidemia: a prospective study of older adults. J Nutr 2021;151:2390–2398.

29. Rimm EB, Williams P, Fosher K, Criqui M, Stampfer MJ. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ 1999;319:1523–1528.

30. Rader DJ, Kathiresan S. Disorders of lipoprotein metabolism. In: Jameson JL, Kasper DL, Longo DL, Fauci AS, Hauser SL, Loscalzo, ed. Harrison’s principles of internal medicine. 20th ed. New York: McGraw-Hill Education, 2018. 31. Kwan TW, Wong SS, Hong Y, et al. Epidemiology of diabetes and atherosclerotic cardiovascular disease among Asian American adults: implications, management, and future directions: a scientific statement from the American Heart Association. Circulation 2023;148:74–94.

32. Lee J, Hoang T, Lee S, Kim J. Association between dietary patterns and dyslipidemia in Korean women. Front Nutr 2022;8:756257.

33. Lichtenstein AH, Appel LJ, Vadiveloo M, et al. 2021 dietary guidance to improve cardiovascular health: a scientific statement from the American Heart Association. Circulation 2021;144:e472.

34. Pasanisi F, Contaldo F, de Simone G, Mancini M. Benefits of sustained moderate weight loss in obesity. Nutr Metab Cardiovasc Dis 2001;11:401–406.

35. Kirkpatrick CF, Sikand G, Petersen KS, et al. Nutrition interventions for adults with dyslipidemia: a clinical perspective from the National Lipid Association. J Clin Lipidol 2023;17:428–451.

36. Sacks FM, Bray GA, Carey VJ, et al. Comparison of weightloss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 2009;360:859–73.

37. Ministry of Health and Welfare, The Korean Nutrition Society. Application of 2020 dietary reference intakes for Koreans. Sejong: Ministry of Health and Welfare, 2021. 38. Hooper L, Martin N, Abdelhamid A, Davey Smith G. Reduction in saturated fat intake for cardiovascular disease. Cochrane Database Syst Rev 2015;(6):CD011737.

39. Hannon BA, Thompson SV, An R, Teran-Garcia M. Clinical outcomes of dietary replacement of saturated fatty acids with unsaturated fat sources in adults with overweight and obesity: a systematic review and meta-analysis of randomized control trials. Ann Nutr Metab 2017;71:107–117.

40. Hooper L, Martin N, Jimoh OF, Kirk C, Foster E, Abdelhamid AS. Reduction in saturated fat intake for cardiovascular disease. Cochrane Database Syst Rev 2020;5:CD011737.

41. Guasch-Ferré M, Satija A, Blondin SA, et al. Meta-analysis of randomized controlled trials of red meat consumption in comparison with various comparison diets on cardiovascular risk factors. Circulation 2019;139:1828–1845.

42. Reynolds A, Mann J, Cummings J, Winter N, Mete E, Te Morenga L. Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. Lancet 2019;393:434–445.

43. Soliman GA. Dietary fiber, atherosclerosis, and cardiovascular disease. Nutrients 2019;11:1155.

45. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021;42:3227–3337.

46. Virani SS, Morris PB, Agarwala A, et al. 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2021;78:960–993.

47. Snetselaar LG, de Jesus JM, DeSilva DM, Stoody EE. Dietary guidelines for Americans, 2020-2025: understanding the scientific process, guidelines, and key recommendations. Nutr Today 2021;56:287–295.

48. Liu H, Peng D. Update on dyslipidemia in hypothyroidism: the mechanism of dyslipidemia in hypothyroidism. Endocr Connect 2022;11:e210002.

49. Wah-Suarez MI, Danford CJ, Patwardhan VR, Jiang ZG, Bonder A. Hyperlipidaemia in primary biliary cholangitis: treatment, safety and efficacy. Frontline Gastroenterol 2019;10:401–408.

50. Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol 2018;14:57–70.

51. Kotwal A, Cortes T, Genere N, et al. Treatment of thyroid dysfunction and serum lipids: a systematic review and meta-analysis. J Clin Endocrinol Metab 2020;105:dgaa672.

52. Mantel-Teeuwisse AK, Kloosterman JM, Maitland-van der Zee AH, Klungel OH, Porsius AJ, de Boer A. Drug-Induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Saf 2001;24:443–456.

53. Donahoo WT, Kosmiski LA, Eckel RH. Drugs causing dyslipoproteinemia. Endocrinol Metab Clin North Am 1998;27:677–697.

54. Boots JM, Christiaans MH, van Hooff JP. Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk. Drugs 2004;64:2047–2073.

55. Winegar DA, Salisbury JA, Sundseth SS, Hawke RL. Effects of cyclosporin on cholesterol 27-hydroxylation and LDL receptor activity in HepG2 cells. J Lipid Res 1996;37:179–191.

56. Myerson M. Lipid management in human immunodeficiency virus. Endocrinol Metab Clin North Am 2016;45:141–169.

57. Nduka C, Sarki A, Uthman O, Stranges S. Impact of antiretroviral therapy on serum lipoprotein levels and dyslipidemias: a systematic review and meta-analysis. Int J Cardiol 2015;199:307–318.

58. Lazarte J, Kanagalingam T, Hegele RA. Lipid effects of sodium-glucose cotransporter 2 inhibitors. Curr Opin Lipidol 2021;32:183–190.

59. Vergès B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia 2015;58:886–899.

60. Eckel RH. The complex metabolic mechanisms relating obesity to hypertriglyceridemia. Arterioscler Thromb Vasc Biol 2011;31:1946–1948.

61. Vaziri ND. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int 2016;90:41–52.

62. Moradi H, Vaziri ND. Molecular mechanisms of disorders of lipid metabolism in chronic kidney disease. Front Biosci (Landmark Ed) 2018;23:146–161.

63. de Carvalho JF, Borba EF, Viana VS, Bueno C, Leon EP, Bonfá E. Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus? Arthritis Rheum 2004;50:3610–3615.

64. Yamamoto H, Tanaka M, Yoshiga S, Funahashi T, Shimomura I, Kihara S. Autoimmune severe hypertriglyceridemia induced by anti-apolipoprotein C-II antibody. J Clin Endocrinol Metab 2014;99:1525–1530.

65. Miyashita K, Lutz J, Hudgins LC, et al. Chylomicronemia from GPIHBP1 autoantibodies. J Lipid Res 2020;61:1365–1376.

66. Green P, Theilla M, Singer P. Lipid metabolism in critical illness. Curr Opin Clin Nutr Metab Care 2016;19:111–115.

67. Gupta M, Liti B, Barrett C, Thompson PD, Fernandez AB. Prevention and management of hypertriglyceridemia-induced acute pancreatitis during pregnancy: a systematic review. Am J Med 2022;135:709–714.

68. Yoneyama K, Nakagawa M. Severe acute pancreatitis due to tamoxifen-induced hypertriglyceridemia. Breast J 2019;25:788–789.